{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T22:33:34Z","timestamp":1793572414879,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T00:00:00Z","timestamp":1481760000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s12325-016-0459-6","type":"journal-article","created":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T13:41:07Z","timestamp":1481809267000},"page":"281-299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management"],"prefix":"10.1007","volume":"34","author":[{"given":"Dave","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Miravitlles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Vogelmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,15]]},"reference":[{"key":"459_CR1","doi-asserted-by":"publisher","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","volume":"3","author":"CD Mathers","year":"2006","unstructured":"Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.","journal-title":"PLoS Med."},{"key":"459_CR2","unstructured":"World Health Organization. Chronic obstructive pulmonary disease. Available at: http:\/\/www.who.int\/respiratory\/copd\/en\/ . Accessed 18 Aug 2016."},{"key":"459_CR3","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(04)16855-4","volume":"364","author":"RA Pauwels","year":"2004","unstructured":"Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet. 2004;364:613\u201320.","journal-title":"Lancet"},{"key":"459_CR4","first-page":"2","volume":"8","author":"M Chan-Yeung","year":"2004","unstructured":"Chan-Yeung M, Ait-Khaled N, White N, Ip MS, Tan WC. The burden and impact of COPD in Asia and Africa. Int J Tuberc Lung Dis. 2004;8:2\u201314.","journal-title":"Int J Tuberc Lung Dis."},{"key":"459_CR5","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Available at: http:\/\/goldcopd.org\/global-strategy-diagnosis-management-prevention-copd-2016\/ . Accessed 18 Aug 2016."},{"key":"459_CR6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1183\/09031936.00051110","volume":"37","author":"R Kessler","year":"2011","unstructured":"Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011;37:264\u201372.","journal-title":"Eur Respir J"},{"key":"459_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12931-014-0122-1","volume":"15","author":"M Miravitlles","year":"2014","unstructured":"Miravitlles M, Worth H, Soler Cataluna JJ, et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir Res. 2014;15:122.","journal-title":"Respir Res"},{"key":"459_CR8","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1185\/03007990903103006","volume":"25","author":"MR Partridge","year":"2009","unstructured":"Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin. 2009;25:2043\u20138.","journal-title":"Curr Med Res Opin"},{"key":"459_CR9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.arbres.2015.11.010","volume":"52","author":"JJ Soler-Cataluna","year":"2016","unstructured":"Soler-Cataluna JJ, Sauleda J, Valdes L, et al. Prevalence and perception of 24-hour symptom patterns in patients with stable chronic obstructive pulmonary disease in Spain. Arch Bronconeumol. 2016;52:308\u201315.","journal-title":"Arch Bronconeumol"},{"key":"459_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2147\/COPD.S48570","volume":"8","author":"D Price","year":"2013","unstructured":"Price D, Small M, Milligan G, Higgins V, Garcia Gil E, Estruch J. Impact of night-time symptoms in COPD: a real-world study in five European countries. Int J Chron Obstruct Pulmon Dis. 2013;8:595\u2013603.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"459_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S2213-2600(14)70001-3","volume":"2","author":"SS Kon","year":"2014","unstructured":"Kon SS, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med. 2014;2:195\u2013203.","journal-title":"Lancet Respir Med."},{"key":"459_CR12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2147\/COPD.S76157","volume":"10","author":"JS Stephenson","year":"2015","unstructured":"Stephenson JS, Cai Q, Mocarski M, Tan H, Doshi JA, Sullivan SD. Impact and factors associated with nighttime and early morning symptoms among patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:577\u201386.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"459_CR13","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3109\/15412555.2013.844784","volume":"10","author":"N Roche","year":"2013","unstructured":"Roche N, Small M, Broomfield S, Higgins V, Pollard R. Real world COPD: association of morning symptoms with clinical and patient reported outcomes. COPD. 2013;10:679\u201386.","journal-title":"COPD."},{"key":"459_CR14","first-page":"1","volume":"6","author":"SM Scharf","year":"2011","unstructured":"Scharf SM, Maimon N, Simon-Tuval T, Bernhard-Scharf BJ, Reuveni H, Tarasiuk A. Sleep quality predicts quality of life in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011;6:1\u201312.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"459_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3109\/13685538.2015.1011614","volume":"18","author":"P Singam","year":"2015","unstructured":"Singam P, Hong GE, Ho C, et al. Nocturia in patients with benign prostatic hyperplasia: evaluating the significance of ageing, co-morbid illnesses, lifestyle and medical therapy in treatment outcome in real life practice. Aging Male. 2015;18:112\u20137.","journal-title":"Aging Male."},{"key":"459_CR16","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.cardfail.2012.05.002","volume":"18","author":"NS Redeker","year":"2012","unstructured":"Redeker NS, Adams L, Berkowitz R, et al. Nocturia, sleep and daytime function in stable heart failure. J Card Fail. 2012;18:569\u201375.","journal-title":"J Card Fail."},{"key":"459_CR17","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.sleep.2011.12.007","volume":"13","author":"TA Omachi","year":"2012","unstructured":"Omachi TA, Blanc PD, Claman DM, et al. Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes. Sleep Med. 2012;13:476\u201383.","journal-title":"Sleep Med"},{"key":"459_CR18","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1183\/09031936.00196713","volume":"43","author":"P Lange","year":"2014","unstructured":"Lange P, Marott JL, Vestbo J, Nordestgaard BG. Prevalence of night-time dyspnoea in COPD and its implications for prognosis. Eur Respir J. 2014;43:1590\u20138.","journal-title":"Eur Respir J"},{"key":"459_CR19","first-page":"389","volume":"10","author":"J Geiger-Brown","year":"2015","unstructured":"Geiger-Brown J, Lindberg S, Krachman S, et al. Self-reported sleep quality and acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:389\u201397.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"459_CR20","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1378\/chest.121.5.1434","volume":"121","author":"K Nishimura","year":"2002","unstructured":"Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121:1434\u201340.","journal-title":"Chest"},{"key":"459_CR21","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1183\/09031936.02.03242002","volume":"20","author":"S Rennard","year":"2002","unstructured":"Rennard S, Decramer M, Calverley PM, et al. Impact of COPD in North America and Europe in 2000: subjects\u2019 perspective of Confronting COPD International Survey. Eur Respir J. 2002;20:799\u2013805.","journal-title":"Eur Respir J"},{"key":"459_CR22","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/j.rmed.2013.06.019","volume":"107","author":"M Miravitlles","year":"2013","unstructured":"Miravitlles M, Ferrer J, Baro E, Lleonart M, Galera J. Differences between physician and patient in the perception of symptoms and their severity in COPD. Respir Med. 2013;107:1977\u201385.","journal-title":"Respir Med"},{"key":"459_CR23","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1080\/15412550903156333","volume":"6","author":"M Cazzola","year":"2009","unstructured":"Cazzola M, Tashkin DP. Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. COPD. 2009;6:404\u201315.","journal-title":"COPD."},{"key":"459_CR24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.pupt.2010.03.003","volume":"23","author":"M Cazzola","year":"2010","unstructured":"Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23:257\u201367.","journal-title":"Pulm Pharmacol Ther"},{"issue":"Suppl 57","key":"459_CR25","first-page":"P4153","volume":"42","author":"C Reisner","year":"2014","unstructured":"Reisner C, Orevillo C, Fernandez C, et al. Pooled analyses of five phase 2b studies support dose selection of glycopyrrolate-formoterol (GFF) MDI (PT003) 18\/9.6 ++g for phase III development. Eur Respir J. 2014;42(Suppl 57):P4153.","journal-title":"Eur Respir J"},{"key":"459_CR26","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1183\/09031936.00200212","volume":"42","author":"ED Bateman","year":"2013","unstructured":"Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42:1484\u201394.","journal-title":"Eur Respir J"},{"key":"459_CR27","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1183\/09031936.00136014","volume":"45","author":"R Buhl","year":"2015","unstructured":"Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015;45:969\u201379.","journal-title":"Eur Respir J"},{"key":"459_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12931-014-0123-0","volume":"15","author":"AD D\u2019Urzo","year":"2014","unstructured":"D\u2019Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, Caracta CF. Efficacy and safety of fixed-dose combinations of aclidinium bromide\/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014;15:123\u201341.","journal-title":"Respir Res"},{"key":"459_CR29","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.rmed.2013.06.001","volume":"107","author":"JF Donohue","year":"2013","unstructured":"Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium\/vilanterol 62.5\/25 mcg in COPD. Respir Med. 2013;107:1538\u201346.","journal-title":"Respir Med"},{"key":"459_CR30","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.rmed.2015.08.002","volume":"109","author":"D Singh","year":"2015","unstructured":"Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium\u00a0+\u00a0olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109:1312\u20139.","journal-title":"Respir Med"},{"key":"459_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1465-9921-14-49","volume":"14","author":"DP Tashkin","year":"2013","unstructured":"Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013;14:49.","journal-title":"Respir Res"},{"key":"459_CR32","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.chest.2016.02.646","volume":"149","author":"L Calzetta","year":"2016","unstructured":"Calzetta L, Rogliani P, Matera MG, Cazzola M. A systematic review with meta-analysis of dual bronchodilation with LAMA\/LABA for the treatment of stable COPD. Chest. 2016;149:1181\u201396.","journal-title":"Chest"},{"key":"459_CR33","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/1471-2466-14-178","volume":"14","author":"D Singh","year":"2014","unstructured":"Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide\/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178\u201389.","journal-title":"BMC Pulm Med."},{"key":"459_CR34","doi-asserted-by":"crossref","unstructured":"D\u2019Urzo A, Singh D, Kerwin E, Lakkis H, Chuecos F, de Miquel G. Efficacy and safety of aclidinium bromide\/formoterol fumarate fixed-dose combination in patients with moderate to severe COPD, stratified by COPD severity. Poster P553 presented at the American Thoracic Society, 2015.","DOI":"10.1183\/13993003.congress-2015.PA1499"},{"key":"459_CR35","unstructured":"Mr\u00f3z R, Scanlon PD, Donohue JF, Molins E, Lakkis H, de Miquel G. Efficacy and safety of aclidinium bromide\/formoterol fumarate fixed-dose combination in a pooled population of patients with COPD, stratified by age. Poster P550 presented at the American Thoracic Society, 2015."},{"key":"459_CR36","doi-asserted-by":"crossref","unstructured":"Bateman E, Chapman K, Rennard S, Lakkis H, Moy ML, Garcia Gil E. Efficacy and safety of aclidinium bromide\/formoterol fumarate fixed-dose combination in patients with moderate to severe COPD, stratified by inhaled corticosteroid use. Poster P552 presented at the American Thoracic Society, 2015.","DOI":"10.1055\/s-0036-1572276"},{"key":"459_CR37","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1378\/chest.85.6.751","volume":"85","author":"DA Mahler","year":"1984","unstructured":"Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85:751\u20138.","journal-title":"Chest"},{"key":"459_CR38","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1183\/09031936.00124013","volume":"43","author":"DA Mahler","year":"2014","unstructured":"Mahler DA, Decramer M, D\u2019Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J. 2014;43:1599\u2013609.","journal-title":"Eur Respir J"},{"key":"459_CR39","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/1471-2466-14-176","volume":"14","author":"D Singh","year":"2014","unstructured":"Singh D, Pujol H, Ribera A, et al. A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting beta2-adrenergic agonist, in asthma; a Phase II, randomized study. BMC Pulm Med. 2014;14:176.","journal-title":"BMC Pulm Med."},{"key":"459_CR40","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1378\/chest.07-0703","volume":"132","author":"DA Mahler","year":"2007","unstructured":"Mahler DA, Waterman LA, Ward J, McCusker C, ZuWallack R, Baird JC. Validity and responsiveness of the self-administered computerized versions of the baseline and transition dyspnea indexes. Chest. 2007;132:1283\u201390.","journal-title":"Chest"},{"key":"459_CR41","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1378\/chest.09-0934","volume":"136","author":"DA Mahler","year":"2009","unstructured":"Mahler DA, Ward J, Waterman LA, McCusker C, ZuWallack R, Baird JC. Patient-reported dyspnea in COPD reliability and association with stage of disease. Chest. 2009;136:1473\u20139.","journal-title":"Chest"},{"key":"459_CR42","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.rmed.2007.12.019","volume":"102","author":"DP Tashkin","year":"2008","unstructured":"Tashkin DP, Littner M, Andrews CP, Tomlinson L, Rinehart M, Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med. 2008;102:479\u201387.","journal-title":"Respir Med"},{"key":"459_CR43","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1081\/COPD-120030829","volume":"1","author":"DA Mahler","year":"2004","unstructured":"Mahler DA, Ward J, Fierro-Carrion G, et al. Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD. COPD. 2004;1:165\u201372.","journal-title":"COPD."},{"key":"459_CR44","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/bcp.12545","volume":"79","author":"D Singh","year":"2015","unstructured":"Singh D. New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. Br J Clin Pharmacol. 2015;79:695\u2013708.","journal-title":"Br J Clin Pharmacol"},{"key":"459_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-11-196","volume":"11","author":"TK Wilcox","year":"2013","unstructured":"Wilcox TK, Chen WH, Howard KA, et al. Item selection, reliability and validity of the Shortness of Breath with Daily Activities (SOBDA) questionnaire: a new outcome measure for evaluating dyspnea in chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2013;11:1\u201310.","journal-title":"Health Qual Life Outcomes."},{"key":"459_CR46","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12955-015-0369-3","volume":"13","author":"M Tabberer","year":"2015","unstructured":"Tabberer M, Brooks J, Wilcox T. A meta-analysis of four randomized clinical trials to confirm the reliability and responsiveness of the Shortness of Breath with Daily Activities (SOBDA) questionnaire in chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2015;13:177.","journal-title":"Health Qual Life Outcomes."},{"key":"459_CR47","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1136\/thoraxjnl-2013-204428","volume":"69","author":"NK Leidy","year":"2014","unstructured":"Leidy NK, Sexton CC, Jones PW, et al. Measuring respiratory symptoms in clinical trials of COPD: reliability and validity of a daily diary. Thorax. 2014;69:443\u20139.","journal-title":"Thorax"},{"key":"459_CR48","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12931-014-0124-z","volume":"15","author":"NK Leidy","year":"2014","unstructured":"Leidy NK, Murray LT, Monz BU, et al. Measuring respiratory symptoms of COPD: performance of the EXACT-Respiratory Symptoms Tool (E-RS) in three clinical trials. Respir Res. 2014;15:124.","journal-title":"Respir Res"},{"key":"459_CR49","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1183\/09031936.00102509","volume":"34","author":"PW Jones","year":"2009","unstructured":"Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34:648\u201354.","journal-title":"Eur Respir J"},{"key":"459_CR50","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1477-7525-11-104","volume":"11","author":"A Hareendran","year":"2013","unstructured":"Hareendran A, Palsgrove AC, Mocarski M, et al. The development of a patient-reported outcome measure for assessing nighttime symptoms of chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2013;11:104.","journal-title":"Health Qual Life Outcomes."},{"key":"459_CR51","first-page":"475","volume":"10","author":"M Mocarski","year":"2015","unstructured":"Mocarski M, Zaiser E, Trundell D, Make BJ, Hareendran A. Evaluation of the psychometric properties of the Nighttime Symptoms of COPD Instrument. Int J Chron Obstruct Pulmon Dis. 2015;10:475\u201387.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"issue":"3","key":"459_CR52","doi-asserted-by":"publisher","first-page":"A179","DOI":"10.1016\/j.jval.2014.03.1044","volume":"17","author":"M Mocarski","year":"2014","unstructured":"Mocarski M, Hareendran A, Jen MH, Zaiser E, Make BJ. Evaluation of the psychometric properties of the Early Morning Symptoms of COPD Instrument (EMSCI). Value Health. 2014;17(3):A179.","journal-title":"Value Health."},{"key":"459_CR53","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3109\/15412555.2011.630248","volume":"9","author":"T Ringbaek","year":"2012","unstructured":"Ringbaek T, Martinez G, Lange P. A comparison of the assessment of quality of life with CAT, CCQ, and SGRQ in COPD patients participating in pulmonary rehabilitation. COPD. 2012;9:12\u20135.","journal-title":"COPD."},{"key":"459_CR54","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.rmed.2013.04.005","volume":"107","author":"MJ Makela","year":"2013","unstructured":"Makela MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107:1481\u201390.","journal-title":"Respir Med"},{"key":"459_CR55","unstructured":"AstraZeneca PLC. Duaklir\u00ae Genuair\u2122 340\u00a0\u00b5g\/12\u00a0\u00b5g inhalation powder Summary of Product Characteristics. Available at: http:\/\/www.medicines.org.uk\/emc\/medicine\/29652 . Accessed 18 Aug 2016."},{"key":"459_CR56","unstructured":"Boehringer Ingelheim Limited. Spiolto Respimat\u00ae Summary of Product Characteristics. Available at: https:\/\/www.medicines.org.uk\/emc\/medicine\/30495 . Accessed 18 Aug 2016."},{"key":"459_CR57","unstructured":"GlaxoSmithKline. Anoro\u00ae Ellipta\u00ae Summary of Product Characteristics. Available at: https:\/\/www.medicines.org.uk\/emc\/medicine\/28949\/ . Accessed 18 Aug 2016."},{"key":"459_CR58","unstructured":"Novartis Pharmaceuticals Ltd. Ultibro\u00ae Breezhaler\u00ae Summary of Product Characteristics. Available at: http:\/\/www.medicines.org.uk\/emc\/medicine\/29533 . Accessed 18 Aug 2016."},{"key":"459_CR59","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S2213-2600(13)70158-9","volume":"1","author":"ML Decramer","year":"2013","unstructured":"Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013;1:524\u201333.","journal-title":"Lancet Respir Med."},{"key":"459_CR60","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1183\/09031936.00127809","volume":"36","author":"T Troosters","year":"2010","unstructured":"Troosters T, Celli B, Lystig T, et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J. 2010;36:65\u201373.","journal-title":"Eur Respir J"},{"key":"459_CR61","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1183\/09031936.00038814","volume":"44","author":"PW Jones","year":"2014","unstructured":"Jones PW, Lamarca R, Chuecos F, et al. Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. Eur Respir J. 2014;44:1156\u201365.","journal-title":"Eur Respir J"},{"issue":"1","key":"459_CR62","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4104\/pcrj.2012.00092","volume":"22","author":"D Price","year":"2013","unstructured":"Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J. 2013;22(1):92\u2013100.","journal-title":"Prim Care Respir J."},{"key":"459_CR63","doi-asserted-by":"crossref","unstructured":"Beier J, Vogelmeier C, Mroz R, et al. Overall and cardiovascular safety of aclidinium\/formoterol fixed-dose combination versus salmeterol\/fluticasone in patients with COPD. Eur Respir J. 2015;46(Suppl 59).","DOI":"10.1183\/13993003.congress-2015.PA989"},{"key":"459_CR64","doi-asserted-by":"crossref","unstructured":"Vogelmeier C, Paggiaro PL, Dorca J, et al. The Efficacy and Safety of Aclidinium\/Formoterol Fixed-Dose Combination Compared with Salmeterol\/Fluticasone in Patients with COPD: Results from a Phase III Study. In: C22. I FEEL FINE NOW: NEW TREATMENTS FOR COPD. Abstract presented at the ATS 2015 International Conference, Denver, Colorado, 15\u201320 May 2015.","DOI":"10.1183\/13993003.congress-2015.PA2960"},{"key":"459_CR65","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-2600(12)70052-8","volume":"1","author":"CF Vogelmeier","year":"2013","unstructured":"Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1:51\u201360.","journal-title":"Lancet Respir Med."},{"key":"459_CR66","first-page":"1015","volume":"10","author":"N Zhong","year":"2015","unstructured":"Zhong N, Wang C, Zhou X, et al. LANTERN: a randomized study of QVA149 versus salmeterol\/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:1015\u201326.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"459_CR67","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12890-015-0092-1","volume":"15","author":"D Singh","year":"2015","unstructured":"Singh D, Worsley S, Zhu CQ, Hardaker L, Church A. Umeclidinium\/vilanterol versus fluticasone propionate\/salmeterol in COPD: a randomised trial. BMC Pulm Med. 2015;15:91.","journal-title":"BMC Pulm Med."},{"key":"459_CR68","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.rmed.2015.04.018","volume":"109","author":"JF Donohue","year":"2015","unstructured":"Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A. Improvements in lung function with umeclidinium\/vilanterol versus fluticasone propionate\/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015;109:870\u201381.","journal-title":"Respir Med"},{"key":"459_CR69","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/COPD.S95055","volume":"11","author":"KM Beeh","year":"2016","unstructured":"Beeh KM, Derom E, Echave-Sustaeta J, et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat\u00ae is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler\u00ae (ENERGITO\u00ae study). Int J Chron Obstruct Pulmon Dis. 2016;11:193\u2013205.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"459_CR70","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1081\/COPD-200050666","volume":"2","author":"DA Mahler","year":"2005","unstructured":"Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005;2:99\u2013103.","journal-title":"COPD."},{"key":"459_CR71","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","volume":"374","author":"JA Wedzicha","year":"2016","unstructured":"Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374:2222\u201334.","journal-title":"N Engl J Med"},{"issue":"Spec Iss","key":"459_CR72","first-page":"3","volume":"11","author":"P Lange","year":"2016","unstructured":"Lange P, Halpin DM, O\u2019Donnell DE, MacNee W. Diagnosis, assessment, and phenotyping of COPD: beyond FEV1. Int J Chron Obstruct Pulmon Dis. 2016;11(Spec Iss):3\u201312.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"459_CR73","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/resp.12690","volume":"21","author":"P Calverley","year":"2016","unstructured":"Calverley P, Vlies B. A rational approach to single, dual and triple therapy in COPD. Respirology. 2016;21:581\u20139.","journal-title":"Respirology"},{"key":"459_CR74","unstructured":"Bethesda (MD): National Library of Medicine (US). Home\u2014ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/ct2\/home . Accessed 18 Aug 2016."},{"key":"459_CR75","unstructured":"Price D, Small M, Sayers J. Characteristics of COPD patients experiencing night-time symptoms\u2014results of a cross-sectional study in five European countries. Abstract presented at the 4th World Asthma and COPD forum, Paris, France, 30 April\u20133 May 2011."},{"key":"459_CR76","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1185\/03007995.2013.857648","volume":"30","author":"P O\u2019Hagan","year":"2014","unstructured":"O\u2019Hagan P, Chavannes NH. The impact of morning symptoms on daily activities in chronic obstructive pulmonary disease. Curr Med Res Opin. 2014;30:301\u201314.","journal-title":"Curr Med Res Opin"}],"updated-by":[{"DOI":"10.1007\/s12325-017-0481-3","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T00:00:00Z","timestamp":1485820800000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0459-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-016-0459-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0459-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T10:08:10Z","timestamp":1658052490000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-016-0459-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,15]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["459"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0459-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,15]]},"assertion":[{"value":"27 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2016","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}